← Leaderboards
Pawel Kalinski
Roswell Park Cancer Institute Corp
$15,491,276
Attributed
$16,753,799
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,633,301 · 18
By mechanism
P01$23,759,640 · 8
P50$4,507,693 · 4
R01$4,387,697 · 3
R21$579,684 · 1
P30$398,587 · 2
Top collaborators
- Eric T Ahrens4 shared
- Amy K Wesa4 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Cameron Riker Macdonald$169,092
- Walter J Storkus$19,974,413
- Yeong Jai Choi$166,758
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsCellsClinical TrialsVaccinationVaccinesIn VitroBaseImmunotherapyDendritic CellsResponsePatternDesignImmuneIn VivoChemokineT-LymphocyteProductionProgramsCancer PatientAntigensMelanomaUniversity Of Pittsburgh Cancer InstituteSafety
Grant awards (70)
Project 1$198,657
P50 · FY2025 · CA · contact PI
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy$1,494,670
P01 · FY2024 · CA · contact PI
Project 2: Local immunotherapy corrects chemokine patterns in ovarian cancer$302,448
P01 · FY2024 · CA · contact PI
Project 1: Combinatorial adjuvants promote uniform and selective intratumoral CTL infiltration in colorectal cancer$262,423
P01 · FY2024 · CA · contact PI
Core A: Administrative Core$41,251
P01 · FY2024 · CA · contact PI
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy$2,875,855
P01 · FY2023 · CA · contact PI
Project 1: Combinatorial adjuvants promote uniform and selective intratumoral CTL infiltration in colorectal cancer$502,126
P01 · FY2023 · CA · contact PI
IRP-3$364,324
P50 · FY2023 · CA · contact PI
Core A: Administrative Core$89,531
P01 · FY2023 · CA · contact PI
Immune Analysis Shared Resource$76,809
P30 · FY2023 · CA · contact PI
Therapeutic Cell Production Shared Resource$76,807
P30 · FY2023 · CA · contact PI
IRP-3$323,091
P50 · FY2022 · CA · contact PI
Immune Analysis Shared Resource$80,797
P30 · FY2022 · CA · contact PI
Therapeutic Cell Production Shared Resource$80,795
P30 · FY2022 · CA · contact PI
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy$2,934,547
P01 · FY2021 · CA · contact PI
Project 1: Combinatorial adjuvants promote uniform and selective intratumoral CTL infiltration in colorectal cancer$510,510
P01 · FY2021 · CA · contact PI
IRP-3$336,539
P50 · FY2021 · CA · contact PI
Core A: Administrative Core$97,916
P01 · FY2021 · CA · contact PI
Therapeutic Cell Production Shared Resource$83,379
P30 · FY2021 · CA · contact PI
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy$2,808,311
P01 · FY2020 · CA · contact PI
Project 1: Combinatorial adjuvants promote uniform and selective intratumoral CTL infiltration in colorectal cancer$485,860
P01 · FY2020 · CA · contact PI
Core A: Administrative Core$97,916
P01 · FY2020 · CA · contact PI
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1$659,506
P50 · FY2017 · CA · contact PI
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1$149,868
P50 · FY2016 · CA · contact PI
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1$628,850
P50 · FY2015 · CA · contact PI
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1$441,496
P50 · FY2014 · CA · contact PI
Directing Tumor-specific T cells to Tumors$1,436,996
P01 · FY2013 · CA · contact PI
MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1$252,036
P50 · FY2013 · CA · contact PI
Tumor-Specific Chemokine Modulation in Colorectal Cancer Versus Melanoma$216,746
P01 · FY2013 · CA · contact PI
Administrative, Statistical, and Regulatory$173,423
P01 · FY2013 · CA · contact PI
Directing Tumor-specific T cells to Tumors$1,651,765
P01 · FY2012 · CA · contact PI
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS$424,804
R01 · FY2012 · CA
Tumor-Specific Chemokine Modulation in Colorectal Cancer Versus Melanoma$337,276
P01 · FY2012 · CA · contact PI
DCs Regulate Chemokine Responsiveness of Melanoma-Specific T Cells$272,347
P50 · FY2012 · CA · contact PI
Administrative, Statistical, and Regulatory$185,492
P01 · FY2012 · CA · contact PI
Directing Tumor-specific T cells to Tumors$152,500
P01 · FY2012 · CA · contact PI
Administrative, Statistical, and Regulatory$19,282
P01 · FY2012 · CA · contact PI
Tumor-Specific Chemokine Modulation in Colorectal Cancer Versus Melanoma$15,856
P01 · FY2012 · CA · contact PI
Directing Tumor-specific T cells to Tumors$1,204,070
P01 · FY2011 · CA · contact PI
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS$492,130
R01 · FY2011 · CA
Tumor-Specific Chemokine Modulation in Colorectal Cancer Versus Melanoma$338,233
P01 · FY2011 · CA · contact PI
DCs Regulate Chemokine Responsiveness of Melanoma-Specific T Cells$236,355
P50 · FY2011 · CA · contact PI
Administrative, Statistical, and Regulatory$170,508
P01 · FY2011 · CA · contact PI
Directing Tumor-specific T cells to Tumors$1,229,591
P01 · FY2010 · CA · contact PI
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS$484,769
R01 · FY2010 · CA
Tumor-Specific Chemokine Modulation in Colorectal Cancer Versus Melanoma$349,289
P01 · FY2010 · CA · contact PI
Regulation of DC Activity by Memory and Effector CD8+ T Cells$268,498
R01 · FY2010 · CA · contact PI
DCs Regulate Chemokine Responsiveness of Melanoma-Specific T Cells$247,084
P50 · FY2010 · CA · contact PI
Administrative, Statistical, and Regulatory$150,199
P01 · FY2010 · CA · contact PI
Directing Tumor-specific T cells to Tumors$1,091,197
P01 · FY2009 · CA · contact PI
NK CELLS INDUCE DCI-MEDIATED ANTI-TUMOR IMMUNITY$558,125
P01 · FY2009 · CA · contact PI
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLS$492,081
R01 · FY2009 · CA
Regulation of DC Activity by Memory and Effector CD8+ T Cells$268,578
R01 · FY2009 · CA · contact PI
DCs Regulate Chemokine Responsiveness of Melanoma-Specific T Cells$245,203
P50 · FY2009 · CA · contact PI
Tumor-Specific Chemokine Modulation in Colorectal Cancer Versus Melanoma$227,763
P01 · FY2009 · CA · contact PI
Administrative, Statistical, and Regulatory$147,279
P01 · FY2009 · CA · contact PI
NK CELLS INDUCE DCI-MEDIATED ANTI-TUMOR IMMUNITY$549,797
P01 · FY2008 · CA · contact PI
DCs Regulate Chemokine Responsiveness of Melanoma-Specific T Cells$152,337
P50 · FY2008 · CA · contact PI
NK CELLS INDUCE DCI-MEDIATED ANTI-TUMOR IMMUNITY$386,608
P01 · FY2007 · CA · contact PI
NK CELLS INDUCE DCI-MEDIATED ANTI-TUMOR IMMUNITY$331,826
P01 · FY2006 · CA · contact PI
Polarized DC as Melanoma Vaccine: Phase 1 Evaluation$286,396
R21 · FY2006 · CA · contact PI
Polarization of Dendritic Cells by CD8 T cells$257,773
R01 · FY2006 · CA · contact PI
NK CELLS INDUCE DCI-MEDIATED ANTI-TUMOR IMMUNITY$332,455
P01 · FY2005 · CA
Polarized DC as Melanoma Vaccine: Phase 1 Evaluation$293,288
R21 · FY2005 · CA
Polarization of Dendritic Cells by CD8 T cells$263,987
R01 · FY2005 · CA
MELANOMA ASSOCIATED T AND DC DYSFUNCTION AND DEATH$301,050
R01 · FY2004 · CA
Polarization of Dendritic Cells by CD8 T cells$263,996
R01 · FY2004 · CA
MELANOMA ASSOCIATED T AND DC DYSFUNCTION AND DEATH$302,063
R01 · FY2003 · CA
Polarization of Dendritic Cells by CD8 T cells$264,893
R01 · FY2003 · CA
MELANOMA ASSOCIATED T AND DC DYSFUNCTION AND DEATH$303,075
R01 · FY2002 · CA